Drug intelligence / Profile preview

dexamethasone + granisetron + ginger

Development stage: Preclinical
Lead developer: Merck
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

This is a combination antiemetic regimen consisting of dexamethasone (a corticosteroid), granisetron (a 5-HT3 receptor antagonist), and ginger (a natural antiemetic). The combination is used for the prevention and management of chemotherapy-induced nausea and vomiting (CINV). Dexamethasone and granisetron have been extensively studied together and shown to be highly effective in controlling both acute and delayed emesis induced by moderately to highly emetogenic chemotherapy regimens. Ginger is added for its complementary antiemetic properties.

Targets

HTR3A (5-hydroxytryptamine receptor 3A)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on dexamethasone + granisetron + ginger.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dexamethasone + granisetron + ginger.

Explore the full profile